Introduction
Cardiovascular disease (CVD) is one of the most serious health problems in the modern world. High levels of plasma low-density lipoprotein cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C) are considered to be the major culprits of atherosclerotic CVD, while LDL-C-lowering therapies have been demonstrated to reduce the risk of CVD development 1) . However, it remains controversial and unclear whether high levels of triglycerides (TGs) occupy the third position in a triad of risk factors for atherogenic dyslipidemia. It is generally believed that other hypertriglyceridemia-associated risk factors participate in the development of CVD.
LPL is a key enzyme for the hydrolysis of core TGs of circulating chylomicron and very-low-density lipoprotein (VLDL) 2) . The incidence of mild to moderate hypertriglyceridemia (＜5.0 mM) has been increasing in accordance with increases in obesity, inactivity, drinking habits, etc. and is particularly associated with insulin resistance. Severe hypertriglyceridemia (＞10.0 mM) is accompanied by genetic and/or functional deficiencies in LPL. The complete or near-complete absence of catalytically active LPL invariably leads to (pTriEx-4-mtGPIHBP1), containing C14F, C68R and C14F/C68R were generated from wild-type (pTriEx-4-wtGPIHBP1) using site-directed mutagenesis (QuikChange kit, Stratagene, La Jolla, CA, USA), and the sequences were confirmed. Each GPIHBP1 expression vector was cotransfected with an LPL-V5 expression vector (pcDNA6-hLPL-V5-6xHis) into HEK293 cells using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA). Two days later, the cells were lysed in RIPA buffer (50 mM Tris-HCl (pH7.4), 5 mM MgCl2, 100 mM KCl, 1 mM EDTA, 10% Glycerol and 1% NP-40), and immunoprecipitation was performed using anti-S protein antibodies (Abcam, Cambridge, UK). A Western blot analysis to detect coimmunoprecipitated LPL was performed using anti-V5-HRP antibodies (Invitrogen, Carlsbad, CA, USA), which were visualized using the enhanced chemiluminescence (ECL) system according to the protocol of the manufacturer (Thermo Fisher Scientific, Rockford, IL, USA).
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Quantification of the GPIHBP1 Protein Levels
HEK293 cells were transfected with wild-type or mutant GPIHBP1 expression vectors. Two days later, the cells were lysed with RIPA buffer and 10 μg of total protein was subjected to SDS-PAGE. Western blot analyses to detect GPIHBP1 were performed as indicated above. The protein levels were normalized according to the GAPDH protein levels and analyzed using the ImageJ software program (National Institutes of Health, USA).
Statistical Analysis
The statistical analyses were performed using Student's t -test for independent samples. The data are expressed as the mean±SEM, and p values smaller than 0.05 were considered to be statistically significant. Statistical significance is displayed as ＊ (p＜0.05), ＊ ＊ (p＜0.01) or ＊ ＊ ＊ (p＜0.005).
Case Presentation
A 54-year-old Japanese woman complaining of an increased frequency of chest pressure while walking was admitted to Sumitomo hospital for a thorough examination of CAD. Her height and body weight were 158 cm and 61 kg, respectively, with a waist circumference of 90 cm. Neither lipemia retinalis, hepatosplenomegaly nor eruptive xanthoma were observed. Her parents had a consanguineous marriage between cousins, and there was no familial history of dyslipidemia or CAD. She had never smoked and had undergone menopause at 48 years of age. The patient's severe hypertriglyceridemia.
Some collaborative molecules are necessary for the complete LPL function. Apolipoprotein (Apo) C2 plays a role as an essential cofactor for the LPL activity, while ApoA5 acts as a modulator of the LPL function. Following case reports of these mutants in humans 3, 4) , two new proteins required for the proper LPL function were identified: lipase maturation factor 1 (LMF1) and GPIHBP1. LMF1 is necessary for the maturation of both LPL and hepatic lipase to become full functional forms 5) . Meanwhile, GPIHBP1 is required for LPL trafficking to the endothelial cell surface, where TG lipolysis occurs 6, 7)
. We herein report the case of a middle-aged Japanese woman with hypertriglyceridemia associated with severe CAD who had novel combined mutations in the GPIHBP1 gene. The severe hypertriglyceridemia was induced by an absent LPL activity, possibly due to instability of mutant GPIHBP1 proteins.
Methods
Patient and Lipid Analysis
The patient was clinically evaluated at Sumitomo Hospital. Written informed consent was obtained from the patient for genetic testing, and the study was approved by the ethics committees of both Sumitomo Hospital and the Division of Health Sciences at Osaka University Graduate School of Medicine. The serum lipid and apolipoprotein levels were measured in commercial laboratories. The LPL mass and activity were determined in postheparin plasma collected 15 minutes after an intravenous injection of heparin sodium (Aventis Pharma Ltd, Tokyo, Japan) at a dose of 50 U/ kg body weight. The LPL mass was measured using a sandwich-ELISA 8) . The lipoprotein lipase activity was determined according to an enzymatic method, as previously reported 9) .
DNA Sequence Analysis
Genomic DNA was extracted from peripheral blood (NucleoSpin ® Blood, MACHEREY-NAGEL, PA). Each exon of LPL, APOA5, APOC2, GPIHBP1 and LMF1 was amplified from the genomic DNA with specific primer sets using PCR (KOD-FX Neo, TOYOBO, Tokyo). The fragments amplified by PCR were directly placed on an ABI377 automatic sequencer (Applied Biosystems, Foster City, CA, USA). The sequences of the primers are shown in the Supplemental Table. Binding of GPIHBP1 to LPL Mutant human GPIHBP1 expression vectors
Results
GPIHBP1 Contained Novel Mutations
We performed a sequence analysis of candidate genes that can induce hypertriglyceridemia, such as LPL, APOC2, APOA5, LMF1 and GPIHBP1 ( Fig. 2A) . LPL itself did not have any mutations in its coding region. In GPIHBP1, we identified two homozygous mutations in a coding region, c.41G＞T and c.202 T＞ C, resulting in C14F and C68R, respectively (Fig. 2B) . The former mutation has been recognized to be a single nucleotide polymorphism (SNP; rs11538388), while the latter mutation is novel.
In addition, we identified heterozygous mutations at c.-3 A＞G and c.553 G＞T (G185C) in APOA5 and at c.-62 T＞G in APOC2 (Fig. 2A) . We did not find any mutations in the LMF1 coding region.
LPL Normally Bound to Mutant GPIHBP1
GPIHBP1 is necessary for the plasma LPL activity because it transports LPL from the basal membrane side of endothelial cells to the intraluminal side 6, 7) . The initial step in this system is an interaction between LPL and GPIHBP1. Therefore, we first tested whether the mutant GPIHBP1 was able to bind to LPL in vitro (Fig. 3A, top panel) . LPL-V5 proteins blood pressure and levels of fasting plasma glucose and HbA1c were 134/76 mmHg, 103 mg/dL and 5.7% (NGSP), respectively. The levels of plasma TG, total cholesterol (TC) and HDL-C were 940 mg/dL, 202 mg/dL and 37 mg/dL, respectively ( Table 1) . The LPL mass and activity were extremely low (19 ng/mL and undetectable, respectively) in the postheparin plasma. The levels of apolipoproteins A1, A2 and B were within the normal limits, while those of C2, C3 and E were elevated. She had no history of diabetes or hypertension.
A computerized tomography (CT) coronary angiogram revealed 99% stenosis at #2 in the small right coronary artery and total occlusion at #14 in the left circumflex branch (Fig. 1) . Subsequent percutaneous transluminal coronary angioplasty was successfully performed.
Recurrent acute pancreatitis had been previously diagnosed. The first episode occurred at 27 years of age during the patient's first pregnancy. The plasma TG and TC levels were 2,640 mg/dL and 460 mg/dL, respectively. One month after recovery from the pancreatitis and a miscarriage, the TG level reduced to 790 mg/dL without any medication. Regarding the second pregnancy at 28 years of age, the patient decided to have an artificial abortion. At the time of the third pregnancy at 30 years of age, a thorough examination of hypertriglyceridemia was performed, and the patient was diagnosed with LPL deficiency. Following total parenteral nutrition to suppress the plasma TG level, the patient successfully had a normal delivery. Thereafter, she stopped attending the hospital for more than 20 years. Complete occlusion at #14 in the left circumflex coronary artery (LCX; arrow heads) and small atherosclerotic right coronary artery (RCA; arrows) was observed on a CT coronary angiogram.
of GPIHBP1. The patient developed severe double vessel CAD, although no atherogenic risk factors other than hypertriglyceridemia were observed. It remains controversial whether chylomicronemia is a risk factor for atherosclerosis. Hyperchylomicronemic patients have high levels of triglycerides with low levels of atherogenic LDL. In addition, triglyceride-rich chylomicrons are considered to be too large to enter the arterial wall 10) . In case reports, human patients with mutations in the LPL gene have exhibited no atherosclerotic lesions [11] [12] [13] . On the other hand, Benlian and Saika demonstrated that patients with hypertriglyceridemia due to LPL missense mutations develop atherosclerotic lesions in the coronary and cervical arteries before 55 years of age 14, 15) . It has been suggested that LPL-deficient patients with atherosclerosis have other atherogenic risk factors, such as smoking, diabetes and hypertension, and that these factors may have a large impact on the progression of atherosclerosis.
Many in vivo animal models and in vitro studies have been conducted to address this problem. The modulation of the amount of LPL in LDL-receptorknockout and apoE-knockout mice leads to both proand antiatherogenic changes [16] [17] [18] [19] , and the overexpression of LPL in Watanabe heritable hyperlipidemic were coimmunoprecipitated by S-tagged wild-type GPIHBP1. The mutant form, C14F/C68R GPI-HBP1, was able to interact with LPL with similar affinity.
The Expressions of Mutant GPIHBP1 Proteins were Reduced
In previous experiments, we noticed that the expression levels of mutant GPIHBP1 were lower than those of wild-type GPIHBP1 (Fig. 3A, bottom panel) . We speculated that the mutant GPIHBP1 was somehow unstable. Hence, we evaluated the expression levels of mutant GPIHBP1 proteins ( Fig. 3B and C) . In order to clarify the effects of each mutation, we used the single mutant GPIHBP1, i.e. C14F and C68R, together with the double mutant. The relative expression levels of mutant GPIHBP1 to those of wild-type GPIHBP1 were reduced to 49.8% (C14F; p＜0.05), 66.3% (C68R; p = 0.15) and 30.3% (C14F/C68R; p＜0.005), respectively.
Discussion
The middle-aged Japanese woman presented in this report had severe hypertriglyceridemia with an undetectable LPL activity owing to double mutations A B eridemia may have been involved in the pathogenesis of accelerated atherosclerosis in this case. GPIHBP1, initially identified to be an HDLbinding protein 26) , has been found to associated with LPL and to serve as a lipolysis platform on endothelial cells 6) . It has also been demonstrated that GPIHBP1 is located on the basolateral surface of capillary endothelial cells and moves across endothelial cells together with bound LPL to the apical surface, where lipolysis occurs 7) . Hence, the absence of GPIHBP1 is accompanied by severe hypertriglyceridemia 6) . In humans, the prevalence of GPIHBP1 mutations has been reported to be 5% among patients with severe hypertriglyceridemia 27) . There have been several reports demonstrating mutations in GPIHBP1 proteins in human patients [28] [29] [30] [31] [32] [33] . The universal clinical feature is chylomicronemia; however, other complications, such as lipemia (WHHL) rabbits exhibits proatherogenic effects 20) . In addition, in vitro studies have shown that chylomicron itself can induce prothrombin activation, platelet aggregation and hemorheological abnormalities 21 22) and that plasma LPL displays antiatherogenic properties at physiological levels. In contrast, LPL in the vascular wall is proatherogenic because it acts as an important bridge between apoB-containing lipoprotein and proteoglycans, retaining atherogenic lipoproteins on the surface of endothelial cells 2, 11, 18) . Meanwhile, macrophage LPL promotes foam cell formation and atherosclerosis 23, 24) . GPIHBP1-knockout mice develop lipid and macrophage-rich arterial atherosclerotic lesions 25) , as observed in the double vessel CAD lesions in the present human patient. Because the LPL activity in macrophages is considered to be intact under conditions of GPIHBP1 hypofunction, a normal macrophage LPL activity with severe hypertriglyc- 
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it is very interesting that both of the affected patients suffered from severe CAD. The accumulation of forthcoming clinical studies of the pathogenesis of atherosclerosis in patients with GPIHBP1 mutant proteins will help to clarify these mechanisms.
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None. retinalis, eruptive xanthomas, hepatomegaly and splenomegaly, have also been variously observed. Only one report involved a man with CAD who required three-vessel coronary artery bypass graft surgery 33) . There was no descriptions of atherogenic risk factors other than hypertriglyceridemia for this patient. The present case, therefore, is the second reported case; however, it should be noted that the patient is a middle-aged woman with double vessel CAD without any risk factors for atherosclerosis.
In this report, we identified combined mutations of GPIHBP1, both of which involve cysteine (C14 and C68). The C14F mutation is recognized to be an SNP; however, the C68R mutation itself and the combined mutations are novel, although other amino acid alterations at C68 have been reported 28, 29, 31) . C68 is one of 10 highly conserved cysteine residues in the Ly6 domain of GPIHBP1 and is predicted to form a three-fingered structure. It has been reported that the C68A mutant does not interfere with trafficking, but rather abolishes LPL binding, different from our results. Since the mechanisms of interaction between LPL and GPIHBP1 remain unclear, this discrepancy may be derived from differences in amino acid alterations. In this case, the mutant GPIHBP1 containing C14F/C68R exhibited a decreased expression compared to wild-type GPIHBP1. There are 10 cysteine residues in GPIHBP1, each pair of which make a disulfide bond. Cysteine 14 resides in the signal peptide region, and it has been reported that C14F mutations result in reduced efficiency of transportation into the endoplasmic reticulum. In addition, Charriere reported mildly reduced protein expressions of mutant GPIHBP1s (C14F, C89F and C14F/C89F) in CHO pgsA-745 cells 30) . In the present case, mild to moderate reductions in the protein levels were observed in the C14F, C68R and C14F/C68R mutants expressing HEK293 cells. There have been no reports regarding this mechanism; however, these mutants may form abnormally unfolded proteins that can be processed quickly. Although having a similar binding affinity to LPL, a reduced protein expression may induce impaired LPL transportation from the basal membrane to the vascular lumen, leading to an overall reduced LPL activity.
Conclusion
We herein reported the second case of a severe CAD patient with novel double mutations in GPI-HBP1. Although the mechanisms underlying the associations between GPIHBP1 mutations and the development of atherosclerosis have not yet been clarified,
